Progabide: a new GABA-mimetic agent in clinical use

Prospective study of tardive dyskinesia incidence in the elderly.

JAMA·1991

The prevalence of tardive dyskinesia.

Journal of clinical psychopharmacology·1991

Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration.

Advances in neurology·1984

Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline).

Acta neurologica Scandinavica. Supplementum·1983

Characterization of Propranolol Use and Outcomes in Traumatic Brain Injury at a Level I Trauma Center.

Clinical neuropharmacology·2026

Review of Medications That Reduce Neurological Deficits in Patients With Traumatic Brain Injury.

Clinical neuropharmacology·2026

Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study.

Clinical neuropharmacology·2026

A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.

Clinical neuropharmacology·2026

Yesterday Once More: Revisiting Catatonia in an Elderly Stroke Patient.

Clinical neuropharmacology·2026

Overlapping Hyperosmolar Therapy in Patients With Elevated and Refractory Intracranial Pressure.

Clinical neuropharmacology·2026

Maximizing Metabolic Synergy: A Review of Dual Incretin Therapy as a Step-Up Strategy Following Glucagon-Like Peptide-1 (GLP-1) Monotherapy Failure or Optimization.

Cureus·2026

Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?

Frontiers in endocrinology·2026

Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.

Canadian journal of kidney health and disease·2026

Model-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwe.

Frontiers in pharmacology·2026

Dynamic structural profiling of PINK1 mutations (T313M and L347P) reveals a vital molecular perturbation namely phospho-Serine 65 ubiquitin recognition point in mitophagy mediated autosomal recessive Parkinson's disease (ARPD).

Frontiers in molecular neuroscience·2026

Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.

Therapeutic advances in neurological disorders·2026

Related Experiment Videos

Progabide: a new GABA-mimetic agent in clinical use

Related Concept Videos

Prospective study of tardive dyskinesia incidence in the elderly.

The prevalence of tardive dyskinesia.

Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration.

Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline).

Characterization of Propranolol Use and Outcomes in Traumatic Brain Injury at a Level I Trauma Center.

Review of Medications That Reduce Neurological Deficits in Patients With Traumatic Brain Injury.

Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study.

A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.

Yesterday Once More: Revisiting Catatonia in an Elderly Stroke Patient.

Overlapping Hyperosmolar Therapy in Patients With Elevated and Refractory Intracranial Pressure.

Maximizing Metabolic Synergy: A Review of Dual Incretin Therapy as a Step-Up Strategy Following Glucagon-Like Peptide-1 (GLP-1) Monotherapy Failure or Optimization.

Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?

Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.

Model-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwe.

Dynamic structural profiling of PINK1 mutations (T313M and L347P) reveals a vital molecular perturbation namely phospho-Serine 65 ubiquitin recognition point in mitophagy mediated autosomal recessive Parkinson's disease (ARPD).

Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.

Related Experiment Videos

Progabide: a new GABA-mimetic agent in clinical use

Related Concept Videos

Related Articles